Sign in

    Fanyi Zhong

    Research Analyst at Oppenheimer & Co. Inc.

    Fanyi Zhong is an Equity Research Associate at Oppenheimer & Co. Inc., specializing in healthcare and biotechnology sector analysis. He actively covers companies such as Cellectar Biosciences and is involved in delivering research insights that inform Oppenheimer's healthcare portfolio. Zhong joined Oppenheimer during the expansion of their healthcare research team in the early 2020s and has contributed to sector outlooks such as the TRT Mid-Year reports. He maintains up-to-date industry licenses and qualifications relevant to equity research but is noted for his analytical support rather than holding principal rankings or published performance metrics.

    Fanyi Zhong's questions to Cellectar Biosciences (CLRB) leadership

    Fanyi Zhong's questions to Cellectar Biosciences (CLRB) leadership • Q2 2025

    Question

    Fanyi Zhong of Oppenheimer & Co. Inc. inquired about the approval pathway status for iapofacine in the European Union and asked about the primary off-target sites of concern based on preclinical biodistribution data for CLR125.

    Answer

    COO Jarrod Longcor and CEO James Caruso explained the US regulatory strategy for iapofacine, noting the NDA package is nearly complete pending funding and a confirmatory study. They are awaiting EMA guidance for the EU path in Q3 or Q4. For CLR125, Longcor stated that tumor uptake is 25-30%, with off-target accumulation below 5% in any single tissue, primarily the liver, which is considered a non-concerning level.

    Ask Fintool Equity Research AI

    Fanyi Zhong's questions to Cellectar Biosciences (CLRB) leadership • Q2 2025

    Question

    Fanyi Zhong of Oppenheimer & Co. Inc. inquired about Cellectar's regulatory alignment with the EU for iapofacine I-131 and asked about the primary off-target sites of concern based on preclinical biodistribution data for CLR125.

    Answer

    Chief Operating Officer Jarrod Longcor explained that for the FDA, the company is finalizing the protocol for a confirmatory study for accelerated approval, with most of the NDA package complete. He noted they are awaiting EMA guidance on conditional approval. For CLR125, Longcor stated that off-target activity is low, with less than 5% in any single tissue, and the liver being the most common but well below concerning levels. President and CEO James Caruso added that the company's confidence in the US regulatory strategy is bolstered by having 12 months of follow-up data and strong results in post-BTKi failure patients.

    Ask Fintool Equity Research AI